Serum chromogranin A is a useful marker for Japanese patients with pancreatic neuroendocrine tumors

Cancer Science

Volumn 105, Issue 11, 2014, Pages 1464-1471

  Hijioka, Masayuki ^a   Ito, Tetsuhide ^a   Igarashi, Hisato ^a   Fujimori, Nao ^a   Lee, Lingaku ^a   Nakamura, Taichi ^a,b   Jensen, Robert T ^b   Takayanagi, Ryoichi ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Chromogranin A; Japan; Pancreatic cancer; Pancreatic neuroendocrine tumors; Proton pump inhibitors

Indexed keywords

CHROMOGRANIN A; TUMOR MARKER;

ADULT; AGED; BLOOD; CANCER GRADING; FEMALE; HUMAN; JAPAN; MALE; METASTASIS; MIDDLE AGED; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; REPRODUCIBILITY; RISK; TUMOR VOLUME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CHROMOGRANIN A; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; NEUROENDOCRINE TUMORS; ODDS RATIO; PANCREATIC NEOPLASMS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; ROC CURVE; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84911432197     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12533     Document Type: Article

References (52)

1. Öberg K, Eriksson B. Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol 2005; 19: 753-81.
2. Modlin IM, Oberg K, Chung DC et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008; 9: 61-72.
3. Yao JC, Hassan M, Phan A et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35, 825 cases in the United States. J Clin Oncol 2008; 26: 3063-72.
4. Ito T, Sasano H, Tanaka M et al. Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol 2010; 45: 234-43.
5. Ito T, Igarashi H, Nakamura K et al. Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis. J Gastroenterol 2014; [Epub ahead of print]; doi: 10.1007/s00535-014-0934-2.
6. Ito T, Igarashi H, Jensen RT. Zollinger-ellison syndrome: recent advances and controversies. Curr Opin Gastroenterol 2013; 29: 650-61.
7. Ito T, Igarashi H, Jensen RT. Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances. J Gastroenterol 2012; 47: 941-60.
8. Yao JC, Shah MH, Ito T et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 514-23.
9. Raymond E, Dahan L, Raoul J-L et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 501-13.
10. Ito T, Okusaka T, Ikeda M et al. Everolimus for advanced pancreatic neuroendocrine tumours: a subgroup analysis evaluating Japanese patients in the radiant-3 trial. Jpn J Clin Oncol 2012; 42: 903-11.
11. Ito T, Okusaka T, Nishida T et al. Phase II study of sunitinib in japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor. Invest New Drugs 2013; 31: 1265-74.
12. Ganeshan D, Paulson E, Duran C, Cabanillas ME, Busaidy NL, Charnsangavej C. Current update on medullary thyroid carcinoma. AJR Am J Roentgenol 2013; 201: W867-76.
13. Kimura T. East meets west: ethnic differences in prostate cancer epidemiology between East Asians and Caucasians. Chin J Cancer 2012; 31: 421-9.
14. Singh S, Law C. Chromogranin A: a sensitive biomarker for the detection and post-treatment monitoring of gastroenteropancreatic neuroendocrine tumors. Expert Rev Gastroenterol Hepatol 2012; 6: 313-34.
15. Ito T, Igarashi H, Jensen RT. Serum pancreastatin: the long sought universal, sensitive, specific tumor marker for neuroendocrine tumors? Pancreas 2012; 41: 505-7.
16. Campana D, Nori F, Piscitelli L et al. Chromogranin A: is it a useful marker of neuroendocrine tumors? J Clin Oncol 2007; 25: 1967-73.
17. Modlin IM, Gustafsson BI, Moss SF, Pavel M, Tsolakis AV, Kidd M. Chromogranin A-biological function and clinical utility in neuro endocrine tumor disease. Ann Surg Oncol 2010; 17: 2427-43.
18. Konecki DS, Benedum UM, Gerdes H-H, Huttner WB. The primary structure of human chromogranin A and pancreastatin. J Biol Chem 1987; 262: 17026-30.
19. Taupenot L, Harper KL, O'Connor DT. The chromogranin-secretogranin family. N Engl J Med 2003; 348: 1134-49.
20. Zissimopoulos A, Vradelis S, Konialis M et al. Chromogranin A as a biomarker of disease activity and biologic therapy in inflammatory bowel disease: a prospective observational study. Scand J Gastroenterol 2014; 498: 942-9.
21. Bech PR, Ramachandran R, Dhillo WS, Martin NM, Bloom SR. Quantifying the effects of renal impairment on plasma concentrations of the neuroendocrine neoplasia biomarkers chromogranin A, chromogranin B, and cocaine- and amphetamine-regulated transcript. Clin Chem 2012; 585: 941-3.
22. Spadaro A, Ajello A, Morace C et al. Serum chromogranin-A in hepatocellular carcinoma: diagnostic utility and limits. World J Gastroenterol 2005; 1113: 1987-90.
23. Kimura N, Yoshida R, Shiraishi S, Pilichowska M, Ohuchi N. Chromogranin A and chromogranin B in noninvasive and invasive breast carcinoma. Endocr Pathol 2002; 132: 117-22.
24. Malaguarnera M, Cristaldi E, Cammalleri L et al. Elevated chromogranin A (CgA) serum levels in the patients with advanced pancreatic cancer. Arch Gerontol Geriatr 2009; 48: 213-7.
25. Lambe M, Trichopoulos D, Hsieh CC, Wuu J, Adami HO, Wide L. Ethnic differences in breast cancer risk: a possible role for pregnancy levels of alpha-fetoprotein? Epidemiology 2003; 14: 85-9.
26. Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO Classification of Tumours of the Digestive System, Vol 3, 4th edn. Lyon: IARC, 2010.
27. Shimosegawa T, Kataoka K, Kamisawa T et al. The revised Japanese clinical diagnostic criteria for chronic pancreatitis. J Gastroenterol 2010; 45: 584-91.
28. Shimosegawa T, Kanno A. Autoimmune pancreatitis in Japan: overview and perspective. J Gastroenterol 2009; 44: 503-17.
29. Nobels FR, Kwekkeboom DJ, Bouillon R, Lamberts SW. Chromogranin A: its clinical value as marker of neuroendocrine tumours. Eur J Clin Invest 1998; 28: 431-40.
30. Chou WC, Hung YS, Hsu JT et al. Chromogranin A is a reliable biomarker for gastroenteropancreatic neuroendocrine tumors in an Asian population of patients. Neuroendocrinology 2012; 95: 344-50.
31. Paik WH, Ryu JK, Song BJ et al. Clinical usefulness of plasma chromogranin a in pancreatic neuroendocrine neoplasm. J Korean Med Sci 2013; 28: 750-4.
32. Nobili E, Pezzilli R, Santini D et al. Autoimmune pancreatitis associated with high levels of chromogranin a, serotonin and 5-hydroxyindoleacetic acid. Case Rep Gastroenterol 2008; 2: 11-7.
33. Sanduleanu S, De Bruïne A, Stridsberg M et al. Serum chromogranin A as a screening test for gastric enterochromaffin-like cell hyperplasia during acid-suppressive therapy. Eur J Clin Invest 2001; 31: 802-11.
34. Mosli HH, Dennis A, Kocha W, Asher LJ, Van Uum SH. Effect of short-term proton pump inhibitor treatment and its discontinuation on chromogranin A in healthy subjects. J Clin Endocrinol Metab 2012; 97: E1731-5.
35. Korse CM, Muller M, Taal BG. Discontinuation of proton pump inhibitors during assessment of chromogranin A levels in patients with neuroendocrine tumours. Br J Cancer 2011; 1058: 1173-5.
36. Nobels FRE, Kwekkeboom DJ, Coopmans W et al. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the a-subunit of glycoprotein hormones. J Clin Endocrinol Metab 1997; 82: 2622-8.
37. Belli SH, Oneto A, Aranda C et al. Chromogranin A as a biochemical marker for the management of neuroendocrine tumors: a multicenter study developed in argentina. Acta Gastroenterol Latinoam 2009; 39: 184-9.
38. Tomassetti P, Migliori M, Simoni P et al. Diagnostic value of plasma chromogranin A in neuroendocrine tumours. Eur J Gastroenterol Hepatol 2001; 13: 55-8.
39. Baudin E, Gigliotti A, Ducreux M et al. Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours. Br J Cancer 1998; 78: 1102-7.
40. Panzuto F, Severi C, Cannizzaro R et al. Utility of combined use of plasma levels of chromogranin A and pancreatic polypeptide in the diagnosis of gastrointestinal and pancreatic endocrine tumors. J Endocrinol Invest 2004; 27: 6-11.
41. Nehar D, Lombard-Bohas C, Olivieri S et al. Interest of chromogranin A for diagnosis and follow-up of endocrine tumours. Clin Endocrinol (Oxf) 2004; 60: 644-52.
42. Cimitan M, Buonadonna A, Cannizzaro R et al. Somatostatin receptor scintigraphy versus chromogranin A assay in the management of patients with neuroendocrine tumors of different types: clinical role. Ann Oncol 2003; 14: 1135-41.
43. Welin S, Stridsberg M, Cunningham J et al. Elevated plasma chromogranin A is the first indication of recurrence in radically operated midgut carcinoid tumors. Neuroendocrinology 2009; 89: 302-7.
44. Ito T, Igarashi H, Jensen RT. Pancreatic neuroendocrine tumors: clinical features, diagnosis and medical treatment: advances. Best Pract Res Clin Gastroenterol 2012; 26: 737-53.
45. Peracchi M, Conte D, Gebbia C et al. Plasma chromogranin A in patients with sporadic gastro-entero-pancreatic neuroendocrine tumors or multiple endocrine neoplasia type 1. Eur J Endocrinol 2003; 148: 39-43.
46. Korse CM, Taal BG, Vincent A et al. Choice of tumour markers in patients with neuroendocrine tumours is dependent on the histological grade. A marker study of chromogranin A, neuron specific enolase, progastrin-releasing peptide and cytokeratin fragments. Eur J Cancer 2012; 48: 662-71.
47. Niina Y, Fujimori N, Nakamura T et al. The current strategy for managing pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1. Gut Liver 2012; 6: 287-94.
48. Glinicki P, Jeske W. Chromogranin A (CgA) - the influence of various factors in vivo and in vitro, and existing disorders on its concentration in blood. Endokrynol Pol 2011; 62(Suppl 1): 25-8.
49. Molina R, Alvarez E, Aniel-Quiroga A et al. Evaluation of chromogranin A determined by three different procedures in patients with benign diseases, neuroendocrine tumors and other malignancies. Tumor Biol 2011; 32: 13-22.
50. Glinicki P, Kapuścińska R, Jeske W. The differences in chromogranin A (CgA) concentrations measured in serum and in plasma by IRMA and ELISA methods. Endokrynol Pol 2010; 61: 346-50.
51. Louthan O. Chromogranin a in physiology and oncology. Folia Biol (Praha) 2011; 57: 173-81.
52. Zatelli MC, Torta M, Leon A et al. Chromogranin A as a marker of neuroendocrine neoplasia: an italian multicenter study. Endocr Relat Cancer 2007; 142: 473-82.